Every 10-Q that Tenet Healthcare Corporation New (THC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow THC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THC filings page.
Tenet Healthcare Corporation reported higher profitability for the quarter ended June 30, 2026. Net operating revenues rose to $5,628 million from $5,271 million, and operating income increased to $1,501 million from $823 million, helped by solid volume growth in both Hospital Operations and Ambulatory Care.
Results were also boosted by $413 million of revenue from contract termination in the quarter and $826 million year‑to‑date related to the Omnibus Agreement with CHI. Net income available to Tenet common shareholders reached $826 million for the quarter and $1,528 million for the first half, with diluted EPS of $9.84 and $17.81, respectively.
Cash from operating activities increased to $2,226 million in the first half of 2026, supporting capital spending of $348 million and share repurchases of $1,360 million, as Tenet bought back 7.021 million shares. Cash and cash equivalents were $2.170 billion at June 30, 2026, with long‑term debt of $13,248 million and full $1,900 million revolver availability.
Tenet Healthcare Corporation reported Q1 2026 net operating revenues of $5,368 million and net income of $906 million, up from $622 million a year earlier. Diluted earnings per share rose to $8.01 from $4.27 as margins improved.
Operating cash flow reached $1,641 million, supported by a $540 million contract termination payment from CommonSpirit Health under an Omnibus Agreement tied to Conifer. Ambulatory Care net operating revenues grew 10.6% to $1,320 million, while hospital admissions and adjusted admissions were roughly flat.
Tenet ended the quarter with $2,967 million in cash and long-term debt of $13,128 million, and repurchased 1.346 million shares for $318 million, leaving $1,172 million authorized for future buybacks. Management also highlights potential future pressures from U.S. healthcare policy changes, including the One Big Beautiful Bill Act.
Tenet Healthcare (THC) reported Q3 2025 results. Net operating revenues were $5,289 million versus $5,126 million a year ago. Operating income was $889 million. Net income available to common shareholders was $342 million, with diluted EPS of $3.86.
Ambulatory Care continued to expand, generating $1,275 million in net operating revenues in the quarter, up from $1,139 million. For the first nine months, operating cash flow reached $2,809 million, supporting capital spending and equity returns. The company repurchased 7,828 thousand shares year‑to‑date at an average price of $151.75, and the board increased the 2024 share repurchase program in July; $1,688 million remained authorized at September 30.
Cash and cash equivalents were $2,975 million, and long‑term debt (net of current portion) was $13,102 million. As of October 22, 2025, shares outstanding were 87,885 thousand. Tenet highlighted a new FASB practical expedient (ASU 2025‑05) it is evaluating and noted U.S. tax law changes enacted in July 2025 that reduce taxable income through bonus depreciation and interest deduction adjustments.